Cytokine and anticytokine therapy in dermatology

Bibliography

• HADDAD JJ: Cytokines and related receptor-mediated signaling pathways. Biochem. Biophys. Res. Commun. (2002) 297(4):700–713.
   PubMed Web of Science ®Google Scholar
• ••Detailed review of cytokines andtheir pathophysiology.
   Google Scholar
• ASADULLAH K, STERRY W, VOLK HD: Analysis of cytokine expression in dermatology. Arch. Berm. (2002) 138:1–8.
   Google Scholar
• HISCOTT J: Introduction: cytokine receptors, signalling pathway, and viruses. Cytokine Growth Factor Rev (2001) 12:135–149.
   Google Scholar
• •Interactions between viruses and cytokine pathways.
   Google Scholar
• MOSMANN TR, CHERWINSKI H, BOND MW, GIEDLIN MA, COFFMAN RL: Two types of murine helper T cell clone, I. Definition according to profiles of lymphokine activities and secreted proteins. Immunol. (1986) 136:2348–2357.
   Google Scholar
• •Relationship between Thl and Th2 cells.
   Google Scholar
• ROMAGNANI S: Biology of human Thl and Th2 cells. I Clin. Immunol. (1995) 15:121–129.
   Web of Science ®Google Scholar
• •Broad review of Thl and Th2 cells.
   Google Scholar
• ROMAGNANI S: Short analytical review: Thl and Th2 in human diseases. Clin. Immunol. Immunopathol. (1996) 80:225–235.
   PubMedGoogle Scholar
• •Analysing the role of Thl and Th2 in different diseases.
   Google Scholar
• BORISH LC, STEINKE JW: Cytokines and chemokines. Allergy Clin. Immunol. (2003) 111(2 Suppl.):S460–S475.
   Google Scholar
• ASADULLAH K, DOCKE WD, HAEU13LER A, STERRY W, VOLK HD: Progression of mycosis fungoides is associated with increasing cutaneous expression of IL-10 mRNA. I Invest. Dermatol. (1996) 107:833–837.
   PubMed Web of Science ®Google Scholar
• •Overexpression of the irnmunosuppressive cytokine IL-10 in mycosis fungoides.
   Google Scholar
• VOLLMER S, MENSSEN A, TROMMLER P, SCHENDEL D, PRINZ JC: T lymphocytes derived from skin lesions of patients with psoriasis vulgaris express a novel cytokine pattern that is distinct from that of T helper Type 1 and T helper Type 2 cells. Eur: j Immunol. (1994) 24:2377–2382.
   PubMed Web of Science ®Google Scholar
• •A new regulatory T cell subset in psoriasis.
   Google Scholar
• OHMEN JD, HANIFIN JM, NICKOLOFF BJ et al.: Overexpression of IL-10 in atopic dermatitis. j. Immunol. (1995) 154:1956–1963.
   PubMed Web of Science ®Google Scholar
• NASHAN D, LUGER TA: Cytokines: current status and prospects in the treatment of skin tumors. Hautarzt (2001) 52:691–696.
   PubMed Web of Science ®Google Scholar
• KIRKWOOD J: Cancer immunotherapy:the interferon-alpha experience. Semin. Oncol. (2002) 29(3 Suppl.
   Google Scholar
• •Broad experiences in the application of interferons.
   Google Scholar
• JONASCH E, HALUSKA FG: Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist (2001) 6:34–55.
   PubMed Web of Science ®Google Scholar
• •A thorough review on IFN.
   Google Scholar
• KIRKWOOD JM, BENDER C, AGARWALA S et al.: Mechanisms and management of toxicities associated with high-dose interferon alfa-26 therapy.,/ Clin. Oncol. (2002) 20(17):3703–3718.
   Google Scholar
• ••Review of the most important toxicities ofINF therapy.
   Google Scholar
• LEGHA SS: Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy. Semin. Oncol. (1997) 24 (1 Suppl. 4):539–543.
   Google Scholar
• HUNCHAREK M, CAUBET JF, MCGARRY R: Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials. Melanoma Res. (2001) 11:75–81.
   PubMed Web of Science ®Google Scholar
• KIRKWOOD JM, STRAWDERMAN MH, ERNSTOFF MS, SMITH TJ, BORDEN EC, BLUM RH: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.1 Clin. Omni (1996) 14:7–17.
   Google Scholar
• ••First randomised, controlled trial showingimpact on survival for INF-a.
   Google Scholar
• KIRKWOOD JM, IBRAHIM JG, SONDAK VK et al.: High- and low-dose interferon alfa-26 in high-risk melanoma: first analysis of intergroup trial E1690/ S9111/C9190.j Clin. Omni (2000) 18:2444–2458.
   Google Scholar
• KIRKWOOD JM, IBRAHIM JG, SOSMAN JA et al.: High-dose interferon alfa-26 significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. Clin. Oncol. (2001) 19:2370–2380.
   Web of Science ®Google Scholar
• •Demonstrating a significant treatment benefit of high-dose interferon versus vaccine.
   Google Scholar
• PEHAMBERGER H, SOYER HP, STEINER A et al.: Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. Clin. Omni (1998) 16:1425–1429.
   Google Scholar
• GROB JJ, DRENO B, DE LA SALMONIERE P et al: Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet (1998) 351:1905–1910.
   Google Scholar
• SCHWARZENTRAUBER DJ: Biologic therapy with interleukin-2: clinical applications. In: Biologic therapy of cancer (2nd Ed.), DeVita VT, Hellmann S, Rosenberg SA (Eds), JB Lippincott, Philadelphia (1995):235–249.
   Google Scholar
• ••A thorough review on IL-2.
   Google Scholar
• ROSENBERG SA, YANG JC, TOPALIAN SL et al: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA (1994) 271:907–913.
   PubMed Web of Science ®Google Scholar
• •Evidence for immunologic therapy to be effective in selected patients.
   Google Scholar
• PHILIP PA, FLAHERTY L: Treatment of malignant melanoma with interleukin-2. Semin. Omni (1997) 24(1 Suppl. 4):S32–S38.
   Google Scholar
• HAUSCHILD A, GARBE C, STOLZ W et al.: Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized Phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG). Br. Cancer (2001) 84:1036–1042.
   Google Scholar
• ENK AH, NASHAN D, RUBBEN A, KNOP J: High dose inhalation interleukin-2 therapy for lung metastases in patients with malignant melanoma. Cancer (2000) 88:2042–2046.
   PubMed Web of Science ®Google Scholar
• ROCHLITZ C, DRENO B, JANTSCHEFF P et al.: Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: Phase II randomized study comparing two dose levels. Cancer Gene Ther. (2002) 9:289–295.
   PubMed Web of Science ®Google Scholar
• OLD L: Tumor necrosis factor (TNF). Science (1985) 23:630–632.
   Google Scholar
• AGGARWAL BB, NATARAJAN K: Tumor necrosis factors: developments during the last decade. Eui: Cytokine Netw. (1996) 7:93–124.
   PubMed Web of Science ®Google Scholar
• •Excellent review on TNE
   Google Scholar
• ROSSI CR, FOLETTO M, PILATI P, MOCELLIN S, USE M: Isolated limb perfusion in locally advanced cutaneous melanoma. Semin. °flea (2002) 29:400–409.
   Google Scholar
• ••A lucid review on limb perfusionin melanoma.
   Google Scholar
• SPITLER LE, GROSSBARD ML, ERNSTOFF MS et al: Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. Gin. °flea (2000) 18:1614–1621.
   Google Scholar
• TODRYK S, BIRCHALL L, ERLICH R, HALANEK N, ORLEANS-LINDSAY JK, DALGLEISH A: Cytokine gene transfection for autologous and allogeneic melanoma vaccines. Adv. Exp. Med. Biol. (2001) 495:365–368.
   PubMed Web of Science ®Google Scholar
• •Cytokine transfection of vaccines generally increases Thl response.
   Google Scholar
• WEBER J, SONDAK VK, SCOTLAND R et al.: Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma. Cancer (2003) 97:186–200.
   PubMed Web of Science ®Google Scholar
• ROBERTSON MJ, CAMERON C, ATKINS MB et al.: Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer. Clin. Cancer Res. (1999) 5:9–16.
   PubMed Web of Science ®Google Scholar
• •Phase I clinical trial of IL-12 in cancer patients.
   Google Scholar
• KANG WK, PARK C, YOON HL, KIM WS, YOON SS, LEE MH: Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a Phase I study. Hum. Gene Thec (2001) 12:671–684.
   PubMed Web of Science ®Google Scholar
• HELGUERA G, MORRISON SL, PENICHET ML: Antibody-cytokine fusion proteins: harnessing the combined power of cytokines and antibodies for cancer therapy. Clin. Immunol (2002) 105:233–246.
   PubMed Web of Science ®Google Scholar
• •Antibody-cytokine fusion proteins as a new therapeutic option.
   Google Scholar
• ROOK AH, GOTTLIEB SL, WOLFE JT et al.: Pathogenesis of cutaneous T-cell lymphoma: implications for the use of recombinant cytokines and photopheresis. Clin. Exp. Immunol (1997) 107:16–20.
   PubMed Web of Science ®Google Scholar
• ASADULLAH K, DOCKE WD, VOLK HD, STERRY W: Cytokines and cutaneous T-cell lymphomas. Exp. Dermatol (1998) 7:314–320.
   PubMed Web of Science ®Google Scholar
• ••A thorough review of the interaction ofcytokines and CTCL.
   Google Scholar
• STADLER R, OTTE HG, LUGER T et al.: Prospective randomized multicenter clinical trial on the use of interferon-2a plus acitretin versus interferon-2a plus PUVA in patients with cutaneous T-cell lymphoma stages land II. Blood (1998) 92:3578–3581.
   PubMed Web of Science ®Google Scholar
• DIPPEL E, SCHRAG H, GOERDT S, ORFANOS CE: Extracorporeal photopheresis and interferon-alpha in advanced cutaneous T-cell lymphoma. Lancet (1997) 350:32–33.
   PubMed Web of Science ®Google Scholar
• ROOK AH, WOOD GS, Y00 EK et al: Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood (1999) 94:902–908.
   PubMed Web of Science ®Google Scholar
• ••Phase I dose escalation trial withrecombinant human IL-12 in CTCL.
   Google Scholar
• TALPUR R, APISARNTHANARAX N, WARD S, DUVIC M: Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK). Leak. Lymphoma (2002) 43:121–126.
   PubMed Web of Science ®Google Scholar
• KOWALZICK L, ROGOZINSKI T, WIMHEUER R et al.: Intralesional recombinant interferon beta-la in the treatment of basal cell carcinoma: results of an open-label multicentre study. Eui: Dermatol (2002) 12:558–561.
   PubMed Web of Science ®Google Scholar
• CHIMENTI S, PERTS K, DI CRISTOFARO S, FARGNOLI MC, TORLONE G: Use of recombinant interferon alfa-26 in the treatment of basal cell carcinoma. Dermatology (1995) 190:214–217.
   PubMed Web of Science ®Google Scholar
• STERRY W, RUZICKA T, HERRERA E et al.: Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion Br. Dermatol (2002) 147:1227–1236.
   Web of Science ®Google Scholar
• ••Two open-label studies comparingdifferent treatment options of imiquimod.
   Google Scholar
• STOCKFLETH E, MEYER T, BENNINGHOFF B et al: A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses. Arch. Dermatol (2002) 138:1498–1502.
   PubMed Web of Science ®Google Scholar
• ••Effectiveness of imiquimod cream inactinic keratosis is demonstrated.
   Google Scholar
• GALATI D, BOCCHINO M, PAIARDINI M, CERVASI B, SILVESTRI G, PIEDIMONTE G: Cell cycle dysregulation during HIV infection: perspectives of a target based therapy. Cuic Drug Targets Immune Endocc Metabol Disord. (2002) 2:53–61.
   PubMedGoogle Scholar
• ••Review of current therapeutic strategies inHIV infection.
   Google Scholar
• KATLAMA C, CARCELAIN G, DUVIVIER C et al.: Interleuldn-2 accelerates CD4 cell reconstitution in HIV-infected patients with severe immunosuppression despite highly active antiretroviral therapy: the ILSTIM study-ANRS 082. AIDS (2002) 16:2027–2034.
   PubMed Web of Science ®Google Scholar
• LEVY Y, CAPITANT C, HOUHOU S et al.: Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial. ANRS 048 study group. Lancet (1999) 353:1923–1929.
   Google Scholar
• ••IL-2 improves immunological function inHIV-1-infected patients.
   Google Scholar
• LANDAU A, BATISSE D, PIKETTY C et al.: Long-term efficacy of combination therapy with interferon-alpha 2b and ribavirin for severe chronic hepatitis C in HIV-infected patients. AIDS (2001) 15:2149–2155.
   PubMed Web of Science ®Google Scholar
• WOOD R, MONTOYA JG, KUNDU SK, SCHWARTZ DH, MERIGAN TC: Safety and efficacy of polyethylene glycol-modified interleukin-2 and zidovudine in human immunodeficiency virus Type 1 infection: a Phase I/II study. Infect. Dis. (1993) 167:519–525.
   Google Scholar
• EMILIE D, BURGARD M, LASCOUX-COMBE C et al.: Early control of HIV replication in primary HIV-1 infection treated with antiretroviral drugs and pegylated IFN alpha: results from the Primoferon A (ANRS 086) Study. Primoferon A Study Group. AIDS (2001) 165:1435–1437.
   Google Scholar
• EVANS LM, ITRI LM, CAMPION M et al.: Interferon-alpha 2a in the treatment of acquired immunodeficiency syndrome-related Kaposi's sarcoma. Immunothec (1991) 10:39–50.
   PubMed Web of Science ®Google Scholar
• •Therapeutic benefit of INF-a in patients with AIDS-related KS.
   Google Scholar
• FRIEDMAN-KIEN A: Management of condylomata acuminata with Alferon N injection, interferon alfa-n3 (human leukocyte derived). Am. Glister Gynecol (1995) 172:1359–1368.
   PubMed Web of Science ®Google Scholar
• GROSS G: Therapy of human papillomavirus infection and associated epithelial tumors. Inter virology (1997) 40:368–377.
   Google Scholar
• •Comprehensive review on treatment options of HPV-associated diseases.
   Google Scholar
• SANTIN AD, HERMONAT PL, RAVAGGI A et al: Interleukin-10 increases Thl cytokine production and cytotoxic potential in human papillomavirus-specific CD8(+) cytotoxic T lymphocytes. J. Virol (2000) 74:4729–4737.
   PubMed Web of Science ®Google Scholar
• KOLDE G, LUGER T, SORG C, SUNDERKOTTER C: Successful treatment of cutaneous leishmaniasis using systemic interferon-gamma. Dermatology (1996) 192:56–60.
   PubMed Web of Science ®Google Scholar
• ASADULLAH K, VOLK HD, STERRY W: Novel immunotherapies for psoriasis. Trends Immunol (2002) 23:47–53.
   PubMed Web of Science ®Google Scholar
• GOTTLIEB SL, GILLEAUDEAU P, JOHNSON R et al.: Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat. Med. (1995) 1:442–447.
   PubMed Web of Science ®Google Scholar
• GOTTLIEB AB, BACHA P, PARKER K, STRAND V: Use of the interleukin-2 fusion protein, DAB389IL-2, for the treatment of psoriasis. Dermatol Thei: (1998) 5:48–63.
   Google Scholar
• •DAB389IL-2 as a new treatment option in psoriasis.
   Google Scholar
• MARTIN A, GUTIERREZ E, MUGLIA J et al.: A multicenter dose-escalation trial with denileukin diftitox (ONTAK, DAB(389)IL-2) in patients with severe psoriasis. J. Am. Acad. Dermatol (2001) 45:871–881.
   PubMed Web of Science ®Google Scholar
• GOEBEL J, STEVENS E, FORREST K, ROSZMAN TL: Daclizumab (Zenapax) inhibits early interleukin-2 receptor signal transduction events. Transpl. Immunol (2000) 8:153–159.
   PubMed Web of Science ®Google Scholar
• •Daclizurnab specifically interferes with IL-2 signalling.
   Google Scholar
• KRUEGER JG, WALTERS TB, MIYAZAWA M et al.: Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. " Am. Acad. Dermatol (2000) 43:448–458.
   Google Scholar
• AUSTIN LM, OZAWA M, KIKUCHI T, WALTERS TB, KRUEGER JG: The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-, interleukin-2, and tumor necrosis factor-, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J. Invest. Dermatol (1999) 113:752–759.
   PubMed Web of Science ®Google Scholar
• •Article on immunological mechanism in psoriasis.
   Google Scholar
• GHORESCHI K, THOMAS P, BREIT S et al.: Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat. Med. (2003) 9:40–46.
   PubMed Web of Science ®Google Scholar
• ••Prospective dose escalation study of IL-4in psoriasis.
   Google Scholar
• MICHEL G, MIRMOHAMMADSADEGH A, OLASZ E et al: Demonstration and functional analysis of IL-10 receptors in human epidermal cells: decreased expression in psoriatic skin, down-modulation by IL-8, and up-regulation by an antipsoriatic glucocorticosteroid in normal cultured keratinocytes. Immunol (1997) 159:6291–6297.
   Web of Science ®Google Scholar
• ••Interesting article about psoriasis andIL-10 receptors.
   Google Scholar
• ASADULLAH K, SABAT R, WIESE A, DOCKE WD, VOLK HD, STERRY W: Interleukin-10 in cutaneous disorders: implications for its pathophysiological importance and therapeutic use. Arch. Dermatol Res. (1999) 291:628–636.
   PubMed Web of Science ®Google Scholar
• ••Appealing review of IL-10 anddermatological diseases.
   Google Scholar
• ASADULLAH K, DOCKE WD, EBELING M et al.: Interleuldn 10 treatment of psoriasis: clinical results of a Phase II trial. Arch. Dermatol (1999) 135:187–192.
   PubMed Web of Science ®Google Scholar
• •Study to determine the safety and clinical effects of IL-10.
   Google Scholar
• REICH K, BRUCK M, GRAFE A, VENTE C, NEUMANN C, GARBE C: Treatment of psoriasis with Interleukin-10. J. Invest. Dermatol (1998) 6:1235–1236.
   Google Scholar
• •Small study showing clinical benefit of IL-10 in psoriasis.
   Google Scholar
• ASADULLAH K, FRIEDRICH M, HANNEKEN S et al: Effects of systemic interleukin-10 therapy on psoriatic skin lesions: histological, immunohistological and molecular biological findings. J. Invest. Dermatol (2001) 116:721–727.
   PubMed Web of Science ®Google Scholar
• KIMBALL AB, KAWAMURA T, TEJURA K et al: Clinical and immunologic assessment of patients with psoriasis in a randomized, double-blind, placebo-controlled trial using recombinant human interleukin 10. Arch. Dermatol (2002) 138:1341–1346.
   PubMed Web of Science ®Google Scholar
• TREPICCHIO WL, OZAWA M, WALTERS TB: Interleukin-11 therapy selectively downregulates Type I cytokine proinflammatory pathways in psoriasis lesions.' Clin. Invest. (1999) 104:1527–1537.
   Google Scholar
• BOZZA M, BLISS JL, DORNER AJ, TREPICCHIO WL: Interleuldn-11 modulates Thl/Th2 cytokine production from activated CD4+ T cells." Interferon Cytokine Res. (2001) 21:21–30.
   PubMed Web of Science ®Google Scholar
• •Aspects of immunomodulation of IL-11.
   Google Scholar
• STICHERLING M, SAUTIER W, SCHRODER JM, CHRISTOPHERS E: Interleukin-8 plays its role at local level in psoriasis vulgaris. Acta Derm. Venereol (1999) 79:4–8.
   PubMed Web of Science ®Google Scholar
• •The role of the cytokine IL-8 and psoriasis.
   Google Scholar
• JIANG WY, CHATTEDEE AD, RAYCHAUDHURI SP, RAYCHAUDHURI SK, FARBER EM: Mast cell density and IL-8 expression in nonlesional and lesional psoriatic skin. Int. J. Dermatol (2001) 40:699–703.
   PubMed Web of Science ®Google Scholar
• •Increased levels of IL-8 in psoriatic plaques induce mast cell migration.
   Google Scholar
• BRITSCHGI M, PICHLER WJ: Acute generalized exanthematous pustulosis, a clue to neutrophil-mediated inflammatory processes orchestrated by T cells. Carr: Opin. Allergy Clin. Immunol (2002) 2:325–331.
   PubMed Web of Science ®Google Scholar
• KRUEGER GC, LOHNER M, ROSKOS L et al.: Clinical trials results: a fully human anti-IL-8 antibody in patients with moderate to severe psoriasis. Poster presented at: Annual Meeting of American Academy of Dermatology Washington, DC, March 2 (2001).
   Google Scholar
• BULFONE-PAUS S, UNGUREANU D, POHL T et at Interleuldn-15 protects from lethal apoptosis in vivo. Nat. Med. (1997) 3:1124–1128.
   PubMed Web of Science ®Google Scholar
• ••Impact of IL-15 on apoptosis.
   Google Scholar
• RUCKERT R, ASADULLAH K, SEIFERT M et al.: Inhibition of keratinocyte apoptosis by IL-15: a new parameter in the pathogenesis of psoriasis? Immunol (2000) 165:2240–2250.
   Google Scholar
• •IL-15 is a new therapeutic approach in psoriasis.
   Google Scholar
• OH CJ, DAS KM, GOTTLIEB AB: Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J. Am. Acad. Dermatol (2000) 42:829–830.
   PubMed Web of Science ®Google Scholar
• KIRBY B, MARSLAND AM,
   Google Scholar
• CARMICHAEL AJ: Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate. Clin. Exp. Dermatol (2001) 26:27–29.
   PubMed Web of Science ®Google Scholar
• GOTTLIEB AB, MASUD S, RAMAMURTHI R: Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. Am. Acad. Dermatol (2003) 48:68–75.
   PubMed Web of Science ®Google Scholar
• MEASE PJ, GOFFE BS, METZ J, VANDERSTOEP A, FINCK B, BURGE DJ: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet (2000) 356:385–390.
   PubMed Web of Science ®Google Scholar
• ••Considering of etanercept as a newtherapeutic option for psoriasis.
   Google Scholar
• GOTTLIEB AB, MATHESON RT, LOWE N, ZITNIK RJ: Efficacy of Enbrel in patients with psorisasis.J. Invest. Dermatol (2002) 119:234 (Abstract).
   Google Scholar
• TAHA RA, LEUNG DY, GHAFFAR O, BOGUNIEWICZ M, HAMID Q: In vivo expression of cytokine receptor mRNA in atopic dermatitis. I Allergy Gin. Immunol (1998) 102:245–250.
   PubMed Web of Science ®Google Scholar
• YOSHIZAWA Y, NOMAGUCHI H, IZAKI S, KITAMURA K: Serum cytokine levels in atopic dermatitis. Gin. Exp. Dermatol (2002) 27:225–229.
   Web of Science ®Google Scholar
• LEUNG DYM: Pathogenesis of atopic dermatitis. I Allgery Clin. Immunol (1999) 104:99–108.
   Google Scholar
• SCHNEIDER LC, BAZ Z, ZARCONE C,ZURAKOWSKI D: Long-term therapy with recombinant interferon-gamma (rIEN-gamma) for atopic dermatitis. Ann. Allergy Asthma Immunol (1998) 80:263–268.
   PubMed Web of Science ®Google Scholar
• •Study showing safety long-term results for recombinant IEN-y in the treatment of AD.
   Google Scholar
• ROZENBAUM M, ROSNER I, PORTNOY E: Remission of Behcet's syndrome with TNF alpha blocking treatment. Ann. Rheum. Dis. (2002) 61:283–284.
   PubMed Web of Science ®Google Scholar
• TAN MH, GORDON M, LEBWOHL O, GEORGE J, LEBWOHL MG: Improvement of pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody. Arch. Dermatol. (2001) 137:930–933.
   PubMed Web of Science ®Google Scholar
• KOBBE G, SCHNEIDER P, ROHR U et al.: Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse anti-TNFalpha antibody. Bone Marrow Transplant. 2001 28:47–49.
   PubMed Web of Science ®Google Scholar
• •Evaluation of infliximab in acute graft-versus-host disease.
   Google Scholar
• VOIGTLANDER C, LUFTL M, SCHULER G, HERTL M: Infliximab (anti-tumor necrosis factor alpha antibody): a novel, highly effective treatment of recalcitrant subcorneal pustular dermatosis (Sneddon-Wilkinson disease). Arch. Dermatol (2001) 137:1571–1574.
   PubMed Web of Science ®Google Scholar
• FISCHER M, FIEDLER E, MARSCH WC, WOHLRAB J: Antitumour necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis. Br. J. Dermatol (2002) 146:707–709.
   PubMed Web of Science ®Google Scholar
• •Inflixirnab as treatment option in toxic epidermal necrolysis.
   Google Scholar
• MARTINEZ F, NOS P, BENLLOCH S, PONCE J: Hidradenitis suppurativa and Crohn's disease: response to treatment with infliximab. Inflamm. Bowel Dis. (2001) 7:323–326.
   PubMed Web of Science ®Google Scholar
• SAPADIN AN, FLEISCHMAJER R: Treatment of scleroderma. Arch. Dermatol (2002) 138:99–105.
   PubMed Web of Science ®Google Scholar
• •Interesting review of treatment options in sderoderma.
   Google Scholar
• SACHER C, RUBBERT A, KONIG C, SCHARFFETTER-KOCHANEK K, KRIEG T, HUNZELMANN N: Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor alpha antagonist etanercept. J. Am. Acad. Dermatol (2002) 46:113–115.
   PubMed Web of Science ®Google Scholar
• •Etanercept in the treatment of bullous autoirnmune disease.
   Google Scholar
• SMITH KJ, SKELTON H: Common variable immunodeficiency treated with a recombinant human IgG, tumour necrosis factor-alpha receptor fusion protein. Br. Dermatol (2001) 144:597–600.
   PubMed Web of Science ®Google Scholar
• WILLIAMS JD, GRIFFITHS CE: Cytokine blocking agents in dermatology. Gin. Exp. Dermatol (2002) 27:585–590.
   Web of Science ®Google Scholar
• ••An up-to date review of new treatmentoptions in dermatology.
   Google Scholar
• BOYVAT A, SISMAN-SOLAK C, GURLER A: Long-term effects of interferon alpha 2A treatment in Behcet's disease. Dermatology (2000) 201:40–43.
   PubMed Web of Science ®Google Scholar
• BERMAN B, FLORES F: Recurrence rates of excised keloids treated with postoperative triamcinolone acetonide injections or interferon alfa-26 injections. Am. Acad. Dermatol (1997) 37:755–757.
   PubMed Web of Science ®Google Scholar
• SMITH KJ, SKELTON HG: Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgGl-Fc fusion complex therapy. Am. Acad. Dermatol (2001) 45:953–956.
   PubMed Web of Science ®Google Scholar
• AKDIS M, TRAUTMANN A, KLUNKER S, BLASER K, AKDIS CA: Cytokine network and dysregulated apoptosis in atopic dermatitis. Acta Odontol Scand. (2001) 59:178–182.
   PubMed Web of Science ®Google Scholar